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Abstract: 
Ribonucleotide Reductase (RNR) is an enzyme responsible for the reduction of ribonucleotides to their corresponding Deoxyribonucleotides 
(DNA), which is a building block for DNA replication and repair mechanisms. The key role of RNR in DNA synthesis and control in cell growth 
has made this an important target for anticancer therapy. Increased RNR activity has been associated with malignant transformation and tumor 
cell growth. In recent years, several RNR inhibitors, including Triapine, Gemcitabine and GTI-2040, have entered the clinical trials. Our current 
work focuses on an attempted to dock this inhibitors Flavin and Phenosafranine to curtail the action of human RNR2. The docked inhibitor Flavin 
and Phenosafranine binds at the active site with THR176, which are essential for free radical formation. The inhibitor must be a radical scavenger 
to destroy the tyrosyl radical or iron metal scavenger. The iron or radical site of R2 protein can react with one-electron reductants, whereby the 
tyrosyl radical is converted to a normal tyrosine residue. However, compounds such as Flavin and Phenosafranine were used in most of the cases 
to reduce the radical activity. The docking study was performed for the crystal structure of human RNR with the radical scavengers Flavin and 
Phenosafranine to inhibit the human RNR2. This helps to understand the functional aspects and also aids in the development of novel inhibitors 
for the human RNR2. 
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Background: 
Ribonucleotide Reductase (RNR) is a ubiquitous cytosolic enzyme in 
the cell, responsible for converting ribonucleotides into 
deoxyribonucleotides, the eventual substrates for DNA polymerase [1-
3], and also repair DNA in all living cells [4]. In mammalian cells, this 
enzyme contains two dissimilar protein components, R1 and R2, 
which are encoded by two different genes located on different 
chromosomes [5]. Protein R1 is a homodimeric structure, with a 
molecular mass of 168kDa, and has substrate and allosteric effector 
sites that control enzyme activity and substrate specificity [3]. Protein 
R2 is a homodimer, with a molecular mass of 88kDa, And forms two 
equivalent dinuclear iron centers that stabilize a tyrosyl free radical, 
required for the initiation of electron transformation during catalysis. 
R1 and R2 proteins interact at their C-terminal ends to form an active 
holoenzyme [3]. 
 
Amidox (3, 4- dihydroxybenzamidoxime), a new polyhydroxy- 
substituted benzoic acid derivative, is a potent inhibitor of the enzyme 
ribonucleotide reductase (RR), which catalyses the de novo synthesis 
of DNA. RR is considered to be an excellent target for cancer 
chemotherapy. In the present study we investigated the antineoplastic 
effects of Amidox alone and in combination with 
Arabinofuranosylcytosine (Ara-c) in HL-60 human promyelocytic 
leukemia cells [6]. Ribonucleotide reductase (RR) is the rate- limiting 
enzyme of de novo DNA synthesis and has been shown to be up 
regulated linked with proliferation and malignant transformation. It 
was therefore identified as an excellent target for ant tumor therapy 
[7]. Daily oral or intravenous administration of the ribonucleotiode 
diphosphate reductase inhibitor, (E)-2’-(fluromethylene) cytidine 
(MDL 101, 731), to nude mice caused rapid regression of colon and 
prostrate xenografts. Studies were performed to optimize dosing 
schedule and route of administration [8]. 
 
The cell division makes it a potential target for designing drug to 
inhibit cell growth, applications in cancer therapy, and the production 
of anti- malaria and trypanosome drugs, antibiotics and anti-viral 
agents against those viruses that have their own RNRs. An increased 
interest in RNR as a target for cancer therapy is seen ever since the 
human ribonucleotide reductase of a new type was identified which is 
regulated by p53. The p53 actively suppresses tumor formation but on 
mutation several forms of cancer are developed. As much as over 80% 
of the human tumors have been found to contain mutations in p53 or in 
the pathway that directly regulates it. Mammalian RNR-R2 is located 
in the cytoplasm and regulated by the cell cycle. The new R2 gene 
product is called p53R2 and found to be located in the nucleus. The 
p53 binds to a sequence in the first intron of p53R2 gene and is 
required for directly activating its transcription. It was reported 
recently that p53 enzyme binds both R2 and p53R2 subunits in testing 
cells but upon exposure to UV radiation, they dissociate from p53 and 
bind to R1. Perhaps the regulation of RNR activity by p53 is more 
complex than activation of P53R2 [4] 
 
Methodology: 
Receptor and ligand data: 
Radical scavengers from R2 protein are very essential for inhibiting 
the RNR activity and DNA replication. The crystal structure of human 
RNR2 of a single subunit (PDB ID: 2IYH) was used for the current 
studies. Based on brief Literature survey [4, 9], the potential radical 
scavengers Flavin and Phenosafranine molecules are constructed using 
Insight [10] and subsequently these small molecules were subjected to 
energy minimization to bring the energy level of the system to global 
minima, structurally stable and free from steric clashes. 
 
Docking: 
The molecules were further subjected to Auto dock 3.0.5 to perform 
the docking studies which use Lamarckian Genetic Algorithm (LGA) 
for about 50 iterations by placing the grid arbitrarily at the active site 
of the crystal structure [11, 12]. To reduce the complexities in the 
binding studies the hetero groups were removed from the crystal 
structure earlier. The ligand bound complexes were further analyzed 




The free energy co efficient for the vander waals for the docked 
receptor and the ligand is 0.1560 and the electrostatic term for the 
docked receptor and the ligand is 0.1465.  It is said earliar that 
Ribonucleotide reductase (RNR) activity is necessary for DNA 
replication and inhibition of this enzyme will inhibits cell division. 
The inhibitor must be ready to destroy the Tyrosyl radical. And thus 
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Tyrosine 176 to reduce the radical activity and inhibit cell division. 
 
Discussion: 
Structural features of human RNR2 subunit 
The human RNR2 structure belongs to all-helical class of protein. R2 
subunit contains a dinuclear ion center and a tyrosyl radical site (Tyr-
176 in human R2), which are essential for initiation of the nucleotide 
reduction process-taking place at the active site in R1. The di-ion 
center of R2 can exist in different oxidation states. If molecular 
oxygen is allowed to react with the diferrous R2 (Fe (II) Fe (II)), it will 
spontaneously oxidize the di-ion center through a series of 
intermediate states, leading to a µ-oxo- bridged diferric ion cluster (Fe 
(III) Fe (III)) and a stable tyrosyl radical [13]. The dinuclear ion center 
is located within a four-helix bundle and is coordinated by Glutamine 
169,266,232 and Histidine 269. The R2 subunit of RNR generates, as 
mentioned above, a tyrosyl radical essential for the reduction of 
ribonucleotides to deoxyribonucleotides in eukaryotes. It is the first 
and second coordination sphere of the di-ion center in each protein that 
determines the outcome of the reaction with oxygen. Therefore, it is of 
great interest. The crystal structure of human RNR2 (PDB ID: 2IYH) 
is shown in Figure1. 
 
Docking studies 
In this paper we have attempted to dock the inhibitor Flavin and 
Riboflavin to curtail the action of human RNR2. Auto DOCK program 
version available at the web site http://www.scripps.edu/pub/olson-
web/doc/autodock/, was used for this study. This program utilizes 
Lamarckian Genetic Algorithm for configurationally search and 
evaluates the energy using grid-based molecular affinity potential. 
Fifty best configurations of the protein-inhibitors complexes were 
retrieved on binding energy. The hydrogen bond and non-bonded 
contacts for the complexes were calculated using the program 
HBPLUS. 
 
Docking of Flavin and Phenosafranine  
The free energy of binding (calculated by adding the final 
intermolecular energy and torsional free energy), docked energy 
(calculated by adding the final intermolecular energy of ligand) and 
the inhibition constant (Ki) for the complex configurations can be used 
to find the best configuration. The docked inhibitor Flavin binds the 
active site region of the human RNR2. The Flavin interacts with the 
active site tyrosine 176, which is essential for free radical formation. 
The binding of Flavin and phenosafranine with human RNR2 are 
shown in secondary structure representation in Figure 2 and 3. The 
diagram represented by displaying the THR176 in stick representation 
and flavin and phenosafranine in wireframe representation. The fifty 
best configuration of RNR1 and Phenosafranine complex is chosen on 
the basis of free energy of binding, docked energy and inhibition 
constant. The Phenosafranine binds the active site of RNR2. The 
Phenosafranine also interacts with the active site tyrosine 176.  
 
Flavin Action 
Upon anaerobic incubation of R2 protein with reduced flavin and the 
reduction of the tyrosyl radical result in the formation of metR2. This 
reaction occurs in the absence of ferrous ion. In their presence, the Fe 
(III) center is reduced to Fe (II), and reduced R2 becomes the final 
product. Admission of oxygen then results in the reformation of active 
R2. The enzyme provides the reduced flavin, which under anaerobic 
conditions transforms R2 into metR2 by scavenging the tyrosyl radical 
[14]. In a second step, together with Fe (II) ions, the flavin reductase 
catalyzes the formation of reduced R2, with its Fe2+ center. Oxygen 
then closes the circle by reforming the radical Fe3+ center of protein 
R2. In the presence of oxygen, the tyrosyl radical is formed; in its 




Figure 1: The Cartoon representation of crystal structure of human RNR R2 subunit which displays the  α-helix and the loop region in distinct 
manner. The structure is rendered using PyMol. 
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Figure 2: The interaction of Flavin with human RNR was performed using Auto Dock 3.0.5 which displays the residue THR176 interacts with 
the inhibitor Flavin. THR176 of Human RNR and the inhibitor molecule Flavin were found intact at the end of the docking. 
 
 
Figure 3: The interaction of phenosafranine with human RNR was performed using Auto Dock 3.0.5 which displays the residue THR176 
interacts with the inhibitor phenosafranine. THR176 of Human RNR and the inhibitor molecule phenosafranine were found intact at the end of 
the docking.  
 
Mechanism of radical scavenging by Flavin molecule 
In anaerobic condition,  the first step, the oxido oxygen atom of ion 
(III) cluster scavenge the hydrogen radical from the acidic hydrogen of 
flavin and form the hydroxyl Fe (III). Another Fe (III) was reduced to 
Fe (II) and that the reductive step precedes oxygen requiring radical 
formation [5, 9]. According to this model a form of R2 containing 
reduced ion (“reduced R2”) should be an intermediate in the reaction. 
Simultaneously the unstable flavin radical (IIa & IIb) hydrogen 
bonded [flavin N-H (of Uracil moiety)] with oxygen atom of oxido-Fe 
(III) and serve as a driving force for the oxido-Fe (III) bond cleavage. Bioinformation   open access 
www.bioinformation.net    Hypothesis
  
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 4(3): 123-126 (2009)    © 2009 Biomedical Informatics 
 
126
To attain the stable aromatic nature, the II b flavin radical eliminates 
one more electron from the piperazine ring and form the yellow color 
oxidized flavin (IV) in the second step. Hydroxyl Fe (III) reacts with 
second hydrogen radical and form one more reduced Fe (II) and water. 
 
Action of Phenosafranine molecule: 
In the anaerobic environment with the presence of Phenosafranine (I), 
the reduction of both the free radical and the ion center takes place. 
Phenosafranine cation first loses one of its protons and forms the 
neural phenosafranine (II) and hydroxyl Fe- (III). One Fe (III) gets 
reduced to Fe (II) at the first step. In the second step, dimethyl amine 
nitrogen donates a pair of electrons to make aromaticity in the 
molecule and the piperazine moiety expels the hydrogen anion from 
N-H. This anion reacts with HO-Fe (II)-R to form water (IV) and 
reduced to Fe (II). After the radical reduction of Fe center, air was 
introduced into the sample and a partial regeneration of both the iron 
center and the radical occurs. 
 
Non bonded interaction:  
The internal non bonded interactions of the Ribonucleotide reductase 
with  Flavin before weeding  is 861 and after weeding is 550 and that 
of phenosafranine before interaction  is 630 and after weeding is 385. 
The internal energy of the unbound extended state of Flavin was 
computed to be -0.313kcal/mol and that of Phenosafranine is -
0.213kcal/mol. It is noted that the Auto dock internal energy of the 




The Human RNR activity is necessary for DNA replication and 
inhibition of this enzyme helps to inhibit cell division. Therefore an 
understanding of the molecular mechanism of RNR is essential for the 
design of new cytostatic drugs. In this paper, the docked inhibitors 
Flavin and Phenosafranine binds at the active cite TYR176, which are 
essential for free radical formation. This mechanism helps to 
understand the functional aspects of human RNR2 and leads to the 
development of novel inhibitors. An increased level of RNR produces 
more DNA, and thus drives the cells through DNA synthesis. In a 
hypoxic environment where the activity of RNR is hampered due to 
lack of oxygen, the level of RNR regulates the production of DNA and 
drives the cells faster through DNA synthesis. This implies that the 
replication machinery in the cells is able to detect the level of DNA, 
when exogenous DNA is supplied. This helps to explore more about 
the structure of Human RNR and its interaction with its inhibitors. 
Based on our current results, the work can be further narrowed 
towards novel leads molecule synthesis by structure based Drug 
discovery approach.  
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